^
    1d
    IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in glioma. (PubMed, Nat Commun)
    However, elevated expression of poliovirus receptor (PVR) and the immune checkpoint T-cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) on tumor-infiltrating leukocytes suggests a potential resistance mechanism to virotherapy. Combining rQNestin34.5 v.2 with TIGIT blockade enhances therapeutic efficacy compared to monotherapy, identifying IDH1-R132H as a potential predictive biomarker for oncolytic virotherapy response.
    Journal • IO biomarker
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1) • IFNG (Interferon, gamma) • TIGIT (T Cell Immunoreceptor With Ig And ITIM Domains 2) • NECTIN1 (Nectin Cell Adhesion Molecule 1)
    |
    IDH1 R132
    |
    linoserpaturev (CAN-3110)
    4d
    VIR-2218-1006: A Phase 2 Study to Evaluate the Safety, Tolerability, and Efficacy of Regimens Containing VIR-2218, VIR-3434, and/or PEG-IFN? in Subjectsnwith Chronic Hepatitis B Virus Infection (2024-513177-48-00)
    P1/2, N=24, Completed, Vir Biotechnology Inc. | Active, not recruiting --> Completed
    Trial completion
    |
    Pegasys (pegylated interferon α -2a)
    6d
    Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer (clinicaltrials.gov)
    P1/2, N=46, Completed, Genelux Corporation | Phase classification: P1b --> P1/2
    Phase classification • IO biomarker
    |
    MUC16 (Mucin 16, Cell Surface Associated)
    |
    Avastin (bevacizumab) • carboplatin • albumin-bound paclitaxel • olvimulogene nanivacirepvec (GL-ONC1)
    1m
    ECLIPSE 2: A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (clinicaltrials.gov)
    P3, N=150, Recruiting, Vir Biotechnology, Inc.
    Trial initiation date
    1m
    NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer (clinicaltrials.gov)
    P2, N=20, Recruiting, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Trial completion date: Sep 2030 --> Dec 2028 | Trial primary completion date: Sep 2030 --> Dec 2028
    Trial completion date • Trial primary completion date
    |
    Opdivo (nivolumab) • Yervoy (ipilimumab) • 5-fluorouracil • oxaliplatin • irinotecan • leucovorin calcium • NC410
    2ms
    EBVision: A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases (clinicaltrials.gov)
    P2, N=190, Active, not recruiting, Pierre Fabre Medicament | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Tab-cel (tabelecleucel)
    2ms
    Evaluating Outcomes in Acute Promyelocytic Leukemia Patients Treated with All-Trans-Retinoic Acid and Arsenic Trioxide. (PubMed, Indian J Hematol Blood Transfus)
    Acute promyelocytic leukemia (APML) is characterized by promyelocytic leukemia retinoic acid receptor alpha (PML-RARA) fusion gene resulting from at (15;17) translocation. While, TLC significantly decreased from baseline in high risk cases to last follow-up (24 × 109/L vs. 9 × 109/L; P = 0.016). Patients with APML can be successfully treated with a combination of ATO and ATRA.
    Journal
    |
    KIT (KIT proto-oncogene, receptor tyrosine kinase) • RARA (Retinoic Acid Receptor Alpha) • CD33 (CD33 Molecule) • PML (Promyelocytic Leukemia) • ANPEP (Alanyl Aminopeptidase, Membrane)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    2ms
    MARCH: Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection (clinicaltrials.gov)
    P2, N=244, Completed, Vir Biotechnology, Inc. | Active, not recruiting --> Completed
    Trial completion
    2ms
    Phase I Clinical Study of DOC1021 (dubodencel) for Adjuvant Immunotherapy of Glioblastoma. (PubMed, medRxiv)
    DOC1021 was safe, feasibly integrated within SOC, and associated with more favorable outcomes in this challenging patient population. Patients who received observation rather than reoperation for worsening MRI contrast-enhancement exhibited superior survival, suggesting an immune-reactive tumor microenvironment manifesting as pseudo-progression. These data supported initiation of a randomized Phase II trial ( NCT06805305 ) for nGBM.
    P1 data • Journal
    |
    MGMT (6-O-methylguanine-DNA methyltransferase) • CD8 (cluster of differentiation 8) • CD4 (CD4 Molecule)
    |
    dubodencel (DOC1021)
    3ms
    QUATRO-APL: Pivotal Open-label Phase 3 Clinical Study of QTX-2101 in Adult Patients With Acute Promyelocytic Leukemia (clinicaltrials.gov)
    P3, N=150, Recruiting, Quetzal Therapeutics
    New P3 trial
    |
    PML (Promyelocytic Leukemia)
    |
    Chr t(15;17)
    |
    Vesanoid (tretinoin) • arsenic trioxide
    3ms
    A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppressed With Bulevirtide (clinicaltrials.gov)
    P3, N=150, Recruiting, Vir Biotechnology, Inc.
    Trial initiation date
    4ms
    A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2 (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, Dana-Farber Cancer Institute | Recruiting --> Active, not recruiting | Trial completion date: Jan 2027 --> Jan 2028 | Trial primary completion date: Jan 2026 --> Jan 2027
    Enrollment closed • Trial completion date • Trial primary completion date
    |
    IDH1 (Isocitrate dehydrogenase (NADP(+)) 1)
    |
    IDH1 mutation • IDH wild-type • IDH1 R132
    |
    cyclophosphamide • linoserpaturev (CAN-3110)